Corvus Pharmaceuticals, Inc

DURECT Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies that treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the SABER Delivery System, which is a patented and versatile depot injectable useful for proteins, peptides and small molecule delivery; the ORADUR sustained release oral gel-cap technology, which is an oral sustained release technology with several potential abuse deterrent properties; and the DURIN Biodegradable Implant, which is a drug-loaded implant system. It also includes the MICRODUR Biodegradable Microparticulates, which is a microspheres injectable system. DURECT also partners with pharmaceutical and biotechnology companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DURECT has five disclosed on-going development programs, of which four are in collaboration with pharmaceutical partners. The company is headquartered in Cupertino, Calif.

VIVUS is a pharmaceutical company focused on the development and commercialization of new therapeutic products addressing obesity and sexual health, having its facilities in Mountain View, Calif. VIVUS has four products that are positioned to enter Phase 3 clinical trials, and one product that has completed Phase 3 evaluation, for which a new drug application has been submitted to the Food and Drug Administration. The pipeline includes QnexaTM, for which a Phase 2 study has been completed for the treatment of obesity, ALISTATM, for which a Phase 2B program is ongoing for the treatment of female sexual arousal disorder. Other products under development include Testosterone MDTS, for which a Phase 2 program has been completed for the treatment of hypoactive sexual desire disorder, and EvamistTM, for which a Phase 3 program has been completed for the treatment of menopausal symptoms. VIVUS has also developed and is marketing MUSE, a treatment for erectile dysfunction.

Portola Pharmaceuticals is a Bay Area–based pharmaceuticals company with a focus on bioresearch and drug development. Their efforts are directed towards global markets, specifically in the treatment of cardiovascular disease and inflammation. Generated from their available business information